Liraglutide HAEGTFTSDVSSYLEGQAA-[Lys([Palm]-[g-Glu]-)]-EFIAWLVRGRG-acid

  • Description

  • Application Data

Description

Liraglutide binds to and activates the GLP-1 (glucagon-like peptide-1) receptor to bring about an increase in insulin secretion and a decrease in glucagon secretion and gastric emptying.

See full description

Application Data

Catalogue number crb1001347
Molecular Weight 3748.9
Sequence (one letter code) HAEGTFTSDVSSYLEGQAA-[Lys([Palm]-[g-Glu]-)]-EFIAWLVRGRG-acid
Sequence (three letter code) H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-[Lys([Palm]-[g-Glu]-)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Purity >95%
Storage -20°C
References

Mehta et al (2017) Liraglutide for weight management: a critical review of the evidence. Obesity science & practice 3(1) 3 PMID: 28392927

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Liraglutide is sold under the brand name ‘Victoza’ and is a medication used to treat diabetes mellitus type 2 and obesity.
Liraglutide binds to and activates the GLP-1 (glucagon-like peptide-1) receptor to bring about an increase in insulin secretion and a decrease in glucagon secretion and gastric emptying.

Liraglutide

Cat No.Pack SizePriceQty.
0.5mg£150.00
1mg£270.00
Bulk Quote